Attorney Docket No. 17227/154

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

13/8

DEC 0 4/2001 ligant:

Michael Kerin McNAMARA

Cinda

IMMUNOGENIC LHRH COMPOSITIONS AND METHODS RELATING THERETO

2/11/0.

Appl. No.:

09/462,089

Filing

05/01/2000

Ewoldt, G.R.

Date:

RECEIVED

DEC 0 7 2001

TECH CENTER 1600/2900

Examiner:
Art Unit:

1644

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents Washington, D.C. 20231 **Box SEQUENCE**

Sir:

In response to the Notice to Comply with Requirements for Sequence Disclosures mailed on November 4, 2001, enclosed are copies of the Sequence Listing and Statement to Support Filing and Submission in accordance with 37 C.F.R. §§ 1.821-1.825. Also enclosed is a diskette containing the Sequence Listing in computer readable form.

Applicants respectfully request examination of the instant application on the merits in due course.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Date

12/4/81

FOLEY & LARDNER

Customer Number: 22428

22428

PATENT TRADEMARK OFFICE

PATENT TRADEMARK OFFIC

Telephone: (202) 672-5475 Facsimile: (202) 672-5399 Respectfully submitted,

Beth A. Burrous

Attorney for Applicant Registration No. 35,087

RECEIVED

DEC 0 7 2001

TECH CENTER 1600/2900



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

ddress: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	
09/462,(05/0 <mark>6(10</mark>	MCNAMARA:	М	017227/015
<u> </u>	(DEC 0 4	w ,	EXAMINER	
	LARDNE		EWOLDT.G	
SUITE 50 3000 K &		CAN OFFICE	ART UNIT	PAPER NUMBER
	ON DC 20007-86	59 6 	1644	10
			DATE MAILED:	10/05/01

Please find below and/or attached an Office communication concerning this application or pr ceeding.

Commissioner of Patents and Trad marks

ACTION DUE 9 GUENSE LISTING
CLIENT/MATTER #
DUE DATE 1104-01
DKTD BY 18

RECEIVED

DEC 0 7 2001

TECH CENTER 1600/2900



UNITED STATES DEPARTMENT OF COMMERCE Pat nt and Trademark Offic COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

69/42*0*89

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT A

ATTORNEY DOCKET NO.



EXAMINER		
ART UNIT	PAPER NUMBER	

Please find below a communication from the EXAMINER in charge DECEIVED

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However 150 1600/2900 this application fails to comply with the requirements of 37 C.F.R. § 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN **30 days** FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §\$ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.


Applicant please note that the Claims and Specification must be amended to include sequences by Sequence Identification Number (SEQ ID:NO._).

Any inquiry concerning this communication should be directed to Dr. Gerald Ewoldt whose telephone number is (703) 308-9805. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Christina Chan whose telephone number is (703) 308-3973. The fax number for the organization where this application is assigned is (703) 308-4242.

G.R. Ewoldt, Ph.D. Patent Examiner Tech Center 1600 September 25, 2001

Patrick J. Nolan, Ph.D. Primary Examiner

Tech Center 1600



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

DEC 0	P (2001	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).		
& TRADE	MARIA	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).		
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).		
		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."		
· ;		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).		
		6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).		
		7. Other:		
	Ар	plicant Must Provide:		
	X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".		
	X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.		
	X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).		
	For	questions regarding compliance to these requirements, please contact:		
	For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support			
		Technical Assistance703-287-0200 To Purchase Patentin Software703-306-2600		
		PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY		